Comparing ceftolozane/tazobactam versus piperacillin/tazobactam as empiric therapy for complicated urinary tract infection in Taiwan: A cost-utility model focusing on gram-negative...

by Guan-Jhou Chen, Sung-Ching Pan, Jason Foo, Chaienna Morel, Wei-Ting Chen, Jann-Tay Wang
Published 2019-10-01

Cost-effectiveness of ceftolozane/tazobactam plus metronidazole versus piperacillin/tazobactam as initial empiric therapy for the treatment of complicated intra-abdominal infection...

by Vimalanand S. Prabhu, Joseph S. Solomkin, Goran Medic, Jason Foo, Rebekah H. Borse, Teresa Kauf, Benjamin Miller, Shuvayu S. Sen, Anirban Basu
Published 2017-10-01

Continuing to Confront COPD International Patient Survey: Economic Impact of COPD in 12 Countries.

by Jason Foo, Sarah H Landis, Joe Maskell, Yeon-Mok Oh, Thys van der Molen, MeiLan K Han, David M Mannino, Masakazu Ichinose, Yogesh Punekar
Published 2016-01-01